Litcius/Paper detail

Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3

Qianying Yuan, Abdul Basit, Wenhua Liang, Rihao Qu, Yi Luan, Chunguang Ren, Ao Li, Xin Xu, Xiaoqing Liu, Chun Yang, Andrew Kuo, Richard W. Pierce, Longbo Zhang, Benjamin E. Turk, Xin Hu, Fangyong Li, Weixue Cui, Run Li, Danxia Huang, Lili Mo, William C. Sessa, Patty J. Lee, Yuval Kluger, Bing Su, Wenwen Tang, Jianxing He, Dianqing Wu

2021Science Translational Medicine15 citationsDOIOpen Access PDF

Abstract

to enhance pulmonary vasculature integrity and promote lung epithelial cell survival and proliferation, leading to increased pulmonary barrier function and resistance to ALI. Thus, pazopanib has the potential to be effective for treating ALI.

Topics & Concepts

PazopanibMedicineLung transplantationLungPulmonary edemaPharmacologyInternal medicineSunitinibRenal cell carcinomaTransplantation: Methods and OutcomesCardiac Ischemia and ReperfusionNeutrophil, Myeloperoxidase and Oxidative Mechanisms
Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3 | Litcius